- In January 2024, Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company, has received FDA approval under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis of the Tarsier-04 Phase 3 trial, evaluating TRS01 eye drops for non-infectious uveitis, including uveitic glaucoma. This approval paves the way for advancing TRS01 towards potential commercialization, strengthening the company’s position in the ophthalmic market
- In February 2019, EyePoint Pharmaceuticals, Inc. has officially launched YUTIQTM in the U.S., a three-year micro-insert FDA-approved for treating chronic non-infectious uveitis affecting the posterior segment of the eye. This launch enhances the company’s portfolio, positioning it as a leader in long-term ophthalmic treatments and expanding its market presence.
Frequently Asked Questions
The market is segmented based on Global Non-Infectious Uveitis Market Segmentation, By Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, and Panuveitis), Treatment Type (Pharmacological Treatment, Surgical Treatment, and Other Therapies), Route of Administration (Oral, Injectable, and Topical), End User (Hospitals and Clinics, Ophthalmic Care Centers, and Homecare Settings) – Industry Trends and Forecast to 2032
.
The Global Non Infectious Uveitis Market size was valued at USD 2.15 USD Billion in 2024.
The Global Non Infectious Uveitis Market is projected to grow at a CAGR of 8.48% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
